Noteworthy

Apr 01, 2010
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Re-examining service provider roles can bring safety and speed on the road to registration.
Mar 01, 2010
Pharmaceutical Executive
Can the combination with Schering-Plough transform the company from an also-ran to a contender in the big push for market share in the developing world?
Mar 01, 2010
Pharmaceutical Executive
Several leading pharmas may already have a drug for a retrovirus linked to chronic fatigue disease. Has medicine's "problem child" finally earned the industry's respect?
Feb 01, 2010
Pharmaceutical Executive
Sales compensation practices are due for an overhaul in 2010.
Feb 01, 2010
Pharmaceutical Executive
The British specialty shop was once a laughing stock. Now it’s one of pharma’s fastest growing mid-size firms, with a patent cliff bridged and a biotech engine of orphan drugs. So why does CEO Angus Russell fret that success might spoil Shire?
Feb 01, 2010
Pharmaceutical Executive
As Genentech's Avastin continues to mature and spread its branches, the company is looking for high profits on the back end.
Jan 27, 2010
Pharmaceutical Executive
In a disruptive era of change, old-fashioned intuition still counts.
Jan 22, 2010
By Pharmaceutical Executive Editors
GAO reviews price hikes in branded drugs, FDA opens up to public, and pharma opens its wallet for Haiti. All on this week's Pharma Unplugged.
Jan 20, 2010
Pharmaceutical Executive
Pharm Exec's 2010 crystal ball reveals an industry in upheaval on many fronts. Is going back to the future the answer?
Jan 13, 2010
Pharmaceutical Executive
A new pharma consortium focuses on securing the supply chain upstream. Pharm Exec interviews Rx360 to learn more.
native1_300x100
lorem ipsum